RxDoctor Payments Data

Dorian Lopez-Bracetty, MD

Interventional Pain Medicine · San Juan, PRNPI 1184848210

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $5,866 of the $7,359 with a category attached, or 79.7%. Medtronic accounts for 77.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $5,573 and has fallen 91.4% since, to $481 in 2025.

$7,359in general payments, 2019–2025

Across 55 payments — averaging $133.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Abbott$985
  • GE HealthCare$390
  • Boston Scientific$247
  • Eli Lilly Export S.A. Puerto Rico Branch$49
  • AbbVie$23

What the payments were for

  • Travel & lodging$5,86680%
  • Food & beverage$1,49320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$39,258
Medicare patients
65
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm53$41,285
BotoxOnabotulinumtoxina18$23,136
Lidocaine111$15,997
Diclofenac Epolamine31$15,033
Buprenorphine41$9,961
Gabapentin285$4,519
Baclofen360$4,093
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen197$4,037
Diclofenac Potassium91$3,834
Tramadol Hcl328$3,186
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen156$2,940
Duloxetine Hcl269$2,918
Tizanidine Hcl378$2,064
Diclofenac Sodium94$2,039
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine15$1,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$23$23,13618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain medicine providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other interventional pain medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →